晚期阿尔茨海默病患者的血浆神经酰胺。
Plasma Sphingomyelins in Late-Onset Alzheimer's Disease.
机构信息
Department of Biological Chemistry, University of California, Irvine, Irvine, CA, USA.
Center for Complex Biological Systems, University of California, Irvine, Irvine, CA, USA.
出版信息
J Alzheimers Dis. 2021;83(3):1161-1171. doi: 10.3233/JAD-200871.
BACKGROUND
Altered plasma levels of sphingolipids, including sphingomyelins (SM), have been found in mouse models of Alzheimer's disease (AD) and in AD patient plasma samples.
OBJECTIVE
This study assesses fourteen plasma SM species in a late-onset AD (LOAD) patient cohort (n = 138).
METHODS
Specimens from control, preclinical, and symptomatic subjects were analyzed using targeted mass-spectrometry-based metabolomic methods.
RESULTS
Total plasma SM levels were not significantly affected by age or cognitive status. However, one metabolite that has been elevated in manifest AD in several recent studies, SM OHC14:1, was reduced significantly in pre-clinical AD and MCI relative to normal controls.
CONCLUSION
We recommend additional comprehensive plasma lipidomics in experimental and clinical biospecimens related to LOAD that might advance the utility of plasma sphingomyelin levels in molecular phenotyping and interpretations of pathobiological mechanisms.
背景
在阿尔茨海默病（AD）的小鼠模型和 AD 患者的血浆样本中发现，鞘脂类，包括神经鞘磷脂（SM）的血浆水平发生了改变。
目的
本研究评估了迟发性 AD（LOAD）患者队列（n = 138）中的 14 种血浆 SM 种类。
方法
使用基于靶向质谱的代谢组学方法分析对照、临床前和有症状受试者的标本。
结果
总血浆 SM 水平不受年龄或认知状态的显著影响。然而，在最近的几项研究中，在显性 AD 中升高的一种代谢物，即 SM OHC14:1，在临床前 AD 和 MCI 中相对于正常对照显著降低。
结论
我们建议在与 LOAD 相关的实验和临床生物标本中进行额外的全面血浆脂质组学研究，这可能会提高血浆神经鞘磷脂水平在分子表型和病理生物学机制解释中的应用。
Zotero 插件